CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Mayne Pharma Group Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Mayne Pharma Group Ltd
1538 Main North Rd
Phone: +61 882092666p:+61 882092666 Adelaide, SA  5106  Australia Ticker: MYXMYX
Business Summary
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing generic pharmaceuticals. The Company operates through three segments: International, Branded Products Division (BPD) and Portfolio Products Division (PPD). Its International segment manufactures and sells branded and generic pharmaceutical product globally and the provision of contract development and manufacturing services to third party customers. The BPD segment distributes medically differentiated specialty products in United States. The PPD segment distributes established products (branded and generic) in the United States on a portfolio basis. The Company's products include Doxycycline Capsules, Oxycodone IR Tablets, Erythromycin Capsules and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20236/30/2023Yes---Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Frank C.Condella 69 9/30/2021 5/30/2018
Chief Executive Officer, Managing Director, Executive Director Shawn P.O' Brien 64 10/1/2022 10/1/2022
Chief Financial Officer AaronGray 8/29/2022 8/29/2022
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Inhibitor Therapeutics Inc 4830 W. Kennedy Blvd., Suite 600 TAMPA FL United States
Libertas Pharma Inc. 1755 North Brown Road Lawrenceville GA United States

Business Names
Business Name
Doryx
Halcygen Pharmaceuticals Limited
HedgePath Pharmaceuticals Inc
13 additional Business Names available in full report.

General Information
Number of Employees: 900 (As of 6/30/2021)
Outstanding Shares: 81,245,827 (As of 12/31/2023)
Shareholders: 12,196
Stock Exchange: ASX
Fax Number: +61 882810284


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024